Antibody-drug conjugates (ADCs) represent a promising approach exemplified by the DESTINY-Breast03 trial of trastuzumab deruxtecan, which demonstrated substantial improvements in overall patient survival for pre-treated metastatic HER2-+ breast cancer (Hurvitz et al., 2023). This evidence concerns the gene ERBB2 and breast cancer.